Leukemias

Leukemia is a cancer that develops in the bone marrow where blood cells are made.

Programs + Services


Blood and Marrow Transplant Program

The Blood and Marrow Transplant Program at Tufts Children's in Boston provides hematopoietic cell transplants for children with cancer and blood disorders.
More information about programs and services


Leukemias and Lymphomas Program

The specialists at the Tufts Children's Hospital have expertise treating childhood leukemia and lymphoma. Learn more and request an appointment.
More information about programs and services

Doctors + Care Team

Jason Law, MD

Jason Law, MD

Accepting New Patients

Virtual Appointments Available

Title(s): Chief, Pediatric Hematology Oncology; Site Principal Investigator, Children’s Oncology Group and Neuroblastoma Medulloblastoma Translational Research Consortium Trials; Director, Pediatric Bone Marrow Transplantation; Assistant Professor, Tufts University School of Medicine
Department(s): Pediatrics, Pediatric Hematology/Oncology
Appt. Phone: 617-636-5535
Fax #: 617-636-7738

Pediatric hematology, oncology, bone marrow transplant

View Full Profile for Jason Law, MD

Blythe G.  Thomson, MD

Blythe G. Thomson, MD

Accepting New Patients

Title(s): Pediatric Hematologist/Oncologist
Department(s): Pediatrics, Pediatric Hematology/Oncology
Appt. Phone: 617-636-5535
Fax #: 617-636-7738

Pediatric Hematology/Oncology

View Full Profile for Blythe G. Thomson, MD

Cathy G. Rosenfield, MD

Cathy G. Rosenfield, MD

Accepting New Patients

Virtual Appointments Available

Title(s): Co-Director, Tufts University School of Medicine Hematology Course; Associate Clinical Professor, Tufts University School of Medicine
Department(s): Pediatrics, Pediatric Hematology/Oncology
Appt. Phone: 617-636-5535
Fax #: 617-636-7738

Hemophilia and other bleeding disorders, prothrombotic disorders, sickle cell and other hemoglobinopathies, general hematology

View Full Profile for Cathy G. Rosenfield, MD

Hannah Fassel, MD

Hannah Fassel, MD

Accepting New Patients

Virtual Appointments Available

Title(s): Hematologist/Oncologist; Assistant Professor, Tufts University School of Medicine
Department(s): Pediatrics, Hematology/Oncology
Appt. Phone: 978-937-6362.
Fax #:

Anemia, bleeding disorders, thrombosis, general hematology, and childhood cancers such as leukemia and lymphoma.

View Full Profile for Hannah Fassel, MD

Laura M.  Wiltsie, DO

Laura M. Wiltsie, DO

Accepting New Patients

Virtual Appointments Available

Title(s): Pediatric Hematologist/Oncologist; Assistant Professor, Tufts University School of Medicine
Department(s): Pediatrics, Hematology/Oncology
Appt. Phone: 617-636-5535
Fax #: 617-636-7738

Solid tumors, brain tumors

View Full Profile for Laura M. Wiltsie, DO

Tishi Shah, MD

Tishi Shah, MD

Accepting New Patients

Virtual Appointments Available

Title(s): Attending Physician, Pediatric Hematology Oncology; Professor, Tufts University School of Medicine
Department(s): Pediatrics, Pediatric Hematology/Oncology
Appt. Phone: 617-636-5535
Fax #: 617-636-7738

Pediatric hematology oncology, vascular anomalies

View Full Profile for Tishi Shah, MD

Research + Clinical Trials


International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones.

This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
More information about research and clinical trials


A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with or without Down syndrome and newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma. Monoclonal antibodies, such as blinatumomab, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as vincristine, dexamethasone, prednisone, prednisolone, pegaspargase, methotrexate, cytarabine, mercaptopurine, doxorubicin, cyclophosphamide, and thioguanine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin decreases the toxic effects of methotrexate. Giving monoclonal antibody therapy with chemotherapy may kill more cancer cells. Giving blinatumomab and combination chemotherapy may work better then combination chemotherapy alone in treating patients with B-ALL. This trial also assigns patients into different chemotherapy treatment regimens based on risk (the chance of cancer returning after treatment). Treating patients with chemotherapy based on risk may help doctors decide which patients can best benefit from which chemotherapy treatment regimens.
More information about research and clinical trials


A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

This phase III trial studies how well inotuzumab ozogamicin and post-induction chemotherapy work in treating patients with high-risk B-cell lymphoblastic lymphoma (B-ALL), mixed phenotype acute leukemia, and B-lymphoblastic lymphoma (B-LLy). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Drugs used in chemotherapy, such as cyclophosphamide, cytarabine, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, thioguanine, vincristine, and pegaspargase, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The goal of the part 1 of the study is to collect information about leukemia and the effects of the first two phases of treatment, called Induction and Consolidation on this cancer. Additionally, this study aims to investigate whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for 3 years from the start of Interim Maintenance in patient with High Risk Favorable (HR-Fav) and HR B-ALL. Another aim is to understand the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B LLy) receiving HR B-ALL therapy. Finally, another goal of this study is to determine the outcomes of subjects with Mixed Phenotype Acute Leukemia (MPAL) with a favorable early response to treatment using High Risk B-cell Acute Lymphoblastic Leukemia therapy.

More information about research and clinical trials


Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

The overall goals of this study are to:

  • To find out if subjects with down syndrome and standard risk acute myeloid leukemia can be treated with less treatment and still have successful outcomes.
  • To find out if subjects with down syndrome and high risk acute myeloid leukemia can be successfully treated with stronger chemotherapy.

More information about research and clinical trials


A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations

This is a randomized Phase 3 trial that will compare efficacy of CPX-351 during Induction 1 and Induction 2 versus standard chemotherapy for children with do novo, non FLT3-mutant AML.
More information about research and clinical trials


International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones. 

This randomized phase III trial studies how well imatihib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
More information about research and clinical trials